Overview

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation. PURPOSE: Phase I/II trial to study the effectiveness of ravuconazole in preventing fungal infections in patients undergoing allogeneic stem cell transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)
Collaborator:
National Cancer Institute (NCI)